BPC-157 + TB-500 “Wolverine Stack” Protocol Guide

BPC-157 and TB-500 together — the “Wolverine stack” — is the most discussed healing protocol in the peptide community. It's also one of the least standardized. Every forum thread has a different protocol. Every Discord has a different dosing recommendation.

The compounds complement each other: BPC-157 targets localized tissue repair and inflammation, while TB-500 (Thymosin Beta-4) works systemically on tissue remodeling and blood vessel formation. Together, they cover more healing pathways than either alone.

This guide doesn't prescribe a protocol. It maps the common structures people use, explains the variables you need to decide on, and — most importantly — defines what to track so you actually know if it's working.

Why the Stack Works (In Theory)

BPC-157 (Body Protection Compound) is a synthetic peptide derived from a gastric protein. Research (primarily animal studies) suggests it promotes:

• Angiogenesis (new blood vessel formation)
• Tendon and ligament repair
• Anti-inflammatory effects
• GI tract healing

TB-500 (Thymosin Beta-4 fragment) is involved in:

• Cell migration to injury sites
• Tissue remodeling and repair
• Reducing inflammation
• Promoting flexibility in damaged tissue

The rationale for stacking: BPC-157 provides targeted, localized repair while TB-500 supports broader systemic healing. Different mechanisms, overlapping goals.

Important caveat: Most evidence is preclinical (animal models). Human clinical trials for these specific compounds are limited. Users are largely self-experimenting, which makes tracking even more critical.

Common Protocol Structures

Based on community usage patterns (aggregated from r/Peptides, forums, and clinic protocols), these are the most common approaches:

Protocol A: Standard 8-Week Healing Cycle

The most commonly reported structure for injury recovery:

Injection count: BPC twice daily (14/week) + TB-500 twice weekly (2/week) = 16 injections per week. This is a serious site rotation challenge.

Protocol B: Loading + Maintenance

A phased approach common in clinic protocols:

Loading phase (weeks 1-4):

• BPC-157: 250-500mcg twice daily
• TB-500: 5mg twice weekly

Maintenance phase (weeks 5-8):

• BPC-157: 250mcg once daily
• TB-500: 2.5mg once weekly

This reduces injection burden over time as initial healing takes effect. The step-down means your vial math changes mid-protocol — something you need to track.

Protocol C: Cycling (5-on-2-off)

Some users run BPC-157 on a 5-on-2-off cycle:

• BPC-157: 250-500mcg daily, Monday-Friday, off weekends
• TB-500: 2-5mg on Monday and Thursday (regardless of BPC cycle)

This creates a scheduling overlap problem: two compounds with different cycling patterns. On any given day, you need to know if BPC is “on” or “off” AND whether it's a TB-500 day.

The Variables You Need to Decide

Before starting, you need to make these decisions (and record them — future-you will want to know):

1. Local vs Systemic Injection

The BPC-157 debate that never ends: inject subcutaneously near the injury site (“local”) or in a standard site like the abdomen (“systemic”)?

• Local injection: Theoretical higher concentration at the injury. Harder to inject (shoulder, knee). Requires more injection sites near the area.
• Systemic injection: Standard subQ abdomen. Easier. The peptide circulates systemically regardless.
• TB-500: Generally injected systemically (abdomen, thigh) since its mechanism is already systemic.

Many users start with local BPC and systemic TB-500. Whatever you choose, log it. If you switch approaches mid-cycle, that's a variable that could affect your results.

2. Reconstitution and Concentration

BPC-157 typically comes in 5mg vials. TB-500 in 5mg or 10mg vials. How much bacteriostatic water you add determines your concentration and draw volume.

Common setups:

• BPC-157 (5mg + 2ml BAC): 2.5mg/ml → 250mcg = 0.1ml = 10 units on U-100
• TB-500 (5mg + 1ml BAC): 5mg/ml → 2.5mg = 0.5ml = 50 units on U-100

Note the volume difference: TB-500 doses are significantly larger than BPC-157 doses. Some users prefer a U-40 syringe for TB-500 draws to make the markings easier to read.

3. Cycle Duration

Standard recommendations range from 4-12 weeks. Common approach:

• Minimum: 4 weeks (most users report noticing changes around week 2-3)
• Standard: 6-8 weeks
• Extended: 8-12 weeks for chronic or severe injuries

Duration should be based on response, not a fixed calendar. This requires tracking.

Inventory Planning

Running out mid-cycle is common and disruptive. Here's the inventory math for an 8-week Protocol A:

BPC-157 (250mcg twice daily, 8 weeks):

• Daily: 500mcg = 0.5mg
• Weekly: 3.5mg
• 8 weeks: 28mg total
• At 5mg/vial: 6 vials needed

TB-500 (2.5mg twice weekly, 8 weeks):

• Weekly: 5mg
• 8 weeks: 40mg total
• At 5mg/vial: 8 vials needed

That's 14 vials to have on hand (or staggered with reorders). Factor in 7-14 day shipping times from most suppliers. Order your week 5-8 supply by week 2-3.

What to Track: The Healing Measurement Problem

Here's the challenge with healing peptides: there's no blood test that tells you “your tendon is 60% healed.” Progress is subjective. That makes tracking both harder and more important.

Daily Tracking (60 seconds)

• Pain level (1-10): Rate at the same time each day. Morning stiffness is different from end-of-day pain.
• Injection log: Which compound, dose, site, time
• Functional test: One repeatable movement that tests the injury. Shoulder? Overhead reach. Knee? Single-leg squat depth. Elbow? Grip strength. Same test, every day.

Weekly Tracking (5 minutes)

• Range of motion assessment: How far can you move the affected joint/area?
• Activity capacity: What can you do this week that you couldn't last week?
• Photo/video: If visible (swelling, bruising), photograph same angle weekly
• Sleep quality: Pain-related sleep disruption often improves before other symptoms
• Inventory check: Remaining vials, days until reorder needed

Why This Data Matters

Without tracking, the Wolverine stack conversation always ends the same way: “I think it helped?” With tracking, you can answer:

• When did pain start decreasing? (Usually week 2-3)
• Did the improvement plateau? At what dose/week?
• Did switching from local to systemic injection change anything?
• Would you run the same protocol again for a future injury?

This last question is the most valuable. A tracked protocol becomes a reusable template. An untracked protocol is a vague memory.

Common Mistakes

1. Starting both compounds simultaneously: If you get a result (or side effect), you won't know which compound caused it. Some users start BPC-157 alone for 3-5 days, then add TB-500.
2. No baseline measurements: Record pain, ROM, and function BEFORE your first injection. Without a baseline, you can't measure improvement.
3. Stopping too early: “I felt better at week 3 so I stopped.” Tissue remodeling takes longer than pain reduction. Most protocols suggest completing the full cycle even after symptoms improve.
4. Ignoring site rotation: 16 injections per week demands serious rotation discipline. This is where lipohypertrophy develops fast.
5. Not tracking vial freshness: BPC-157 is particularly sensitive to degradation. Know when you reconstituted each vial and don't use vials past their window.

When to Stop

The decision to end a cycle should be based on your tracked data:

• Goal achieved: Pain at 1-2/10, full ROM restored, functional test back to normal
• Plateau for 2+ weeks: If improvement has stalled despite consistent dosing, additional weeks may not add benefit
• Maximum cycle duration reached: 12 weeks is generally the upper limit before a washout period
• Adverse effects: Any unexpected symptoms warrant evaluation and potentially stopping

Supplies Checklist

• Bacteriostatic water (30ml)
• U-100 insulin syringes (29g)
• Alcohol prep pads
• Sharps disposal container

Related

• BPC-157 reconstitution guide: 5mg in 2ml BAC water
• Injection site rotation: why it matters
• How to track a 5-on-2-off cycling schedule
• How long do reconstituted peptides last?
• Peptide inventory math nobody does

Disclaimer: This is educational information about commonly reported BPC-157 and TB-500 protocols, not medical advice. These compounds are sold for research purposes. Human clinical data is limited. Consult a qualified healthcare provider before starting any injectable protocol.